Micron's Long-Term Agreements Reinforce Durability, But Valuation Keeps Rating at WAIT

What happened

Micron delivered a record fiscal year driven by AI memory scarcity, with Q3 revenue of $41.5B and gross margin near 85%, and management now expects supply to tighten further through 2030 on signed long-term agreements. The stock has already re-rated to $1,076, up over 500% from a year ago, reflecting these fundamentals but also leaving little margin for error. Strategic customer agreements with take-or-pay terms and $18B in expected deposits reduce downside, but they also cap upside via ceiling prices near recent market levels. Competitor capacity additions and slowing DRAM price growth are early signs that the scarcity cycle may be maturing. As a result, the investment case remains one of durable strength, not fresh acceleration, supporting a wait-and-see stance.

Implication

The valuation already discounts sustained AI memory leadership, so upside from here requires accelerating earnings revisions, not just stable results. Near-term catalysts include the September 30 report and updates on FY2027 HBM allocations and deposits, which could shift the risk-reward. If management confirms tightening supply and rising deposits, the bull case strengthens; if competitors ramp faster or pricing growth slows below 10% QoQ, downside to $850 becomes more likely. The stock's long-term potential remains tied to HBM4E success and the durability of long-term contracts, but cyclical risks persist. Until more clarity emerges, maintaining a patient approach with buy plans near $900 and trim discipline above $1,200 is prudent.

Thesis delta

No material shift to the thesis; the new article reinforces the durability of Micron's strategic agreements and management's expectation of tightening supply, already reflected in the WAIT rating. The core judgment stands: fundamentals are exceptional but valuation is full, with upside capped by contract ceilings and downside protected by take-or-pay terms. The market's focus remains on September 30 guidance and 2027 supply-demand balance.